Parent IMPACT-III: Development and Validation of an Inflammatory Bowel Disease-specific Health-related Quality-of-life Measure
| Autor: | Clair Talmadge, Sharon Shih, Bonney Reed, Anthony R. Otley, Mary Gray Stolz, Amy Grant, Grace K. Cushman, Ronald L. Blount |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Parents
Adolescent business.industry Gastroenterology Discriminant validity Reproducibility of Results Validity Disease Inflammatory Bowel Diseases medicine.disease Inflammatory bowel disease Proxy Article Convergent validity Surveys and Questionnaires Pediatrics Perinatology and Child Health Quality of Life Criterion validity medicine Humans Child business Psychosocial Depression (differential diagnoses) Clinical psychology |
| Zdroj: | J Pediatr Gastroenterol Nutr |
| ISSN: | 1536-4801 0277-2116 |
| DOI: | 10.1097/mpg.0000000000002540 |
| Popis: | OBJECTIVES: The present study aimed to validate the parent-proxy IMPACT-III (IMPACT-III-P) in a sample of youth diagnosed with inflammatory bowel disease (IBD). Parent-proxy report measures are standard for pediatric psychosocial assessment, and the IMPACT-III-P will provide a more comprehensive representation of HRQOL. Reliability and validity analyses were conducted. METHODS: Parents (N = 50) of youth 8 to 17 years with IBD reported on their child’s HRQOL (IMPACT-III-P and PedsQL-4.0) and depression (BASC-2); youth reported on their HRQOL (child IMPACT-III), pain interference (PROMIS Pain Interference), and disease symptoms; and physicians completed measures of disease activity. RESULTS: Criterion validity was established as the IMPACT-III-P was strongly, positively associated with the PedsQL (r = 0.59, P < 0.001). Convergent validity was supported as higher IMPACT-III-P scores were associated with less pain interference (r = −0.41, P < 0.01) and lower depression (r = −0.41, P < 0.01). Discriminant validity was partially supported, as higher IMPACT-III-P scores were associated with lower child-reported symptoms (r = −0.41, P < 0.01), but scores did not differ based on inactive, mild, or moderate/severe disease activity groups as rated by physicians. Internal consistency, parent-child agreement, and item-level analyses revealed strong reliability. CONCLUSIONS: The IMPACT-III-P demonstrated strong validity and reliability. Parents and children had similar reports of HRQOL, with parents rating child HRQOL slightly lower. Findings support the use of the IMPACT-III-P for youth 8 to 17 years old to use in accordance with the child IMPACT-III to provide valuable information regarding HRQOL in youth with IBD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text